Theriva Biologics (TOVX)
XASE:TOVX
Want to see TOVX full AI Analyst Report?
Top Page
Theriva Biologics
(NYSE MKT:TOVX)
Select Model
Select Model
Rating:51Neutral
Price Target:
$0.28
▲(41.50% Upside)
Action:Reiterated
Date:05/09/26
The score is primarily held down by weak financial performance (limited revenue, large ongoing losses, and continued cash burn alongside declining equity). Technical indicators provide some support with improving price trends and positive momentum, while corporate events are mixed—encouraging progress toward a Phase 3 program but ongoing warrant-approval delays and financing uncertainty. Valuation remains unattractive due to losses (negative P/E) and no dividend yield data.
Positive Factors
Regulatory alignment to Phase 3
FDA agreement on a pivotal Phase 3 protocol is a durable de-risking event: it clarifies endpoints, dosing and adaptive interim analyses, enabling a single global pivotal strategy. This materially improves the program’s regulatory path, partnerability and ability to attract development financing over the next 2–6 months.
Negative Factors
Sustained cash burn
Persistent negative operating and free cash flow (~-$14.4M TTM) means the company depends on external capital to fund development. Even with some improvement versus prior year, ongoing burn creates continual financing need and possible dilution risk if development timelines extend or enrollment costs rise.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory alignment to Phase 3
FDA agreement on a pivotal Phase 3 protocol is a durable de-risking event: it clarifies endpoints, dosing and adaptive interim analyses, enabling a single global pivotal strategy. This materially improves the program’s regulatory path, partnerability and ability to attract development financing over the next 2–6 months.
Read all positive factors
Theriva Biologics (TOVX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.02M
Dividend YieldN/A
Average Volume (3M)8.88M
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue GrowthN/A
EPS Growth87.76%
CountryUS
Employees20
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.53
Shares Outstanding45,892,670
10 Day Avg. Volume25,882,304
30 Day Avg. Volume8,875,558
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap-0.17
Enterprise Value/Revenue-7.45
Enterprise Value/Gross Profit-8.10
Enterprise Value/Ebitda0.10
Forecast
1Y Price Target
$2.50Price Target Upside1150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.23
Revenue Forecast (FY)$29.37M
Theriva Biologics Business Overview & Revenue Model
Company Description
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiot...
How the Company Makes Money
As a clinical-stage biotechnology company, Theriva Biologics has historically not generated meaningful recurring revenue from product sales because it does not have an approved commercial therapy. Its funding has therefore primarily come from exte...
Theriva Biologics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 276.00K | -108.00K | 0.00 | 0.00 | 0.00 | -87.00K |
| EBITDA | -21.55M | -14.91M | -19.29M | -21.96M | -19.20M | -14.19M |
| Net Income | -21.46M | -25.25M | -25.65M | -18.35M | -19.68M | -14.27M |
Balance Sheet | ||||||
| Total Assets | 38.25M | 38.24M | 35.35M | 55.22M | 71.86M | 70.36M |
| Cash, Cash Equivalents and Short-Term Investments | 14.43M | 13.06M | 11.61M | 23.18M | 41.79M | 67.33M |
| Total Debt | 2.07M | 2.63M | 1.56M | 2.15M | 1.68M | 1.53M |
| Total Liabilities | 22.85M | 22.86M | 16.29M | 15.52M | 17.30M | 4.96M |
| Stockholders Equity | 15.40M | 15.38M | 19.07M | 39.70M | 54.56M | 65.41M |
Cash Flow | ||||||
| Free Cash Flow | -14.40M | -16.70M | -16.94M | -19.20M | -19.20M | -12.90M |
| Operating Cash Flow | -14.37M | -16.67M | -16.94M | -19.00M | -19.08M | -12.89M |
| Investing Cash Flow | -35.00K | -35.00K | -1.00K | -202.00K | -4.40M | -14.00K |
| Financing Cash Flow | 18.99M | 18.19M | 5.50M | 625.00K | -1.93M | 74.00M |
Theriva Biologics Technical Analysis
Negative
0.20
Price Trends
0.29
Negative
0.24
Positive
0.29
Negative
Market Momentum
>-0.01
Positive
43.90
Neutral
49.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TOVX, the sentiment is Negative. The current price of 0.2 is below the 20-day moving average (MA) of 0.32, below the 50-day MA of 0.29, and below the 200-day MA of 0.29, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 43.90 is Neutral, neither overbought nor oversold. The STOCH value of 49.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TOVX.
Theriva Biologics Risk Analysis
Theriva Biologics disclosed 62 risk factors in its most recent earnings report. Theriva Biologics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Theriva Biologics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $13.02M | -0.54 | -209.36% | ― | ― | 87.76% | |
49 Neutral | $7.95M | -0.21 | -197.11% | ― | ― | 99.30% | |
47 Neutral | $5.19M | -0.50 | -157.24% | ― | ― | 49.11% | |
43 Neutral | $4.97M | -0.46 | -46.34% | ― | ― | 74.58% |
* Healthcare Sector Average
TOVX
Theriva Biologics
0.28
-0.19
-40.00%
GLMD
Galmed Pharmaceuticals
0.73
-0.75
-50.88%
MTNB
Matinas BioPharma
0.87
0.06
7.65%
CNSP
CNS Pharmaceuticals
5.03
-7.09
-58.50%
Theriva Biologics Corporate Events
Business Operations and Strategy
Theriva Biologics Highlights Positive VCN-01 Pancreatic Cancer Data
Positive
Apr 17, 2026
On April 17, 2026, Theriva Biologics announced that new tumor response, biomarker and subgroup data from its VIRAGE Phase 2b clinical trial of VCN-01 plus gemcitabine/nab-paclitaxel in newly diagnosed metastatic pancreatic cancer will be presented...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Theriva Biologics Faces Delays in Warrant Approval Meeting
Negative
Apr 9, 2026
On April 9, 2026, Theriva Biologics was unable to convene a Special Meeting of Stockholders because an insufficient number of common shares were present or represented by proxy to constitute a quorum, preventing a vote on proposals tied to warrant...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Theriva Biologics Advances VCN-01 Into Pivotal Phase 3
Positive
Mar 23, 2026
On March 23, 2026, Theriva Biologics reported that a recent Type B End-of-Phase 2 meeting with the U.S. Food and Drug Administration yielded broad agreement on the design of a pivotal Phase 3 trial of VCN-01 plus gemcitabine/nab-paclitaxel for fir...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.